Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3345254rdf:typepubmed:Citationlld:pubmed
pubmed-article:3345254lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C0684224lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C0009519lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C0206190lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C0009498lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C0205245lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C1704259lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C1705987lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C1879313lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C0205088lld:lifeskim
pubmed-article:3345254lifeskim:mentionsumls-concept:C1523987lld:lifeskim
pubmed-article:3345254pubmed:issue1lld:pubmed
pubmed-article:3345254pubmed:dateCreated1988-4-13lld:pubmed
pubmed-article:3345254pubmed:abstractTextEndotoxin-stimulated human peritoneal macrophages were cultured in serum-free medium with agarose beads. Monospecific antibodies to human C3c, C3g, C5, C6, C7, C8, C9 and to C9-neoantigen bound to the beads. This shows that activated C3 and the terminal complement complex (TCC), made from complement components C5 to C9, were generated on the beads. De novo synthesis was confirmed by agarose binding of tritium-labelled protein. Moreover, C3-derivatives and C9-neoantigen were detected on normal serum-treated agarose beads but not on beads kept in factor B-depleted or heat-inactivated sera, implying that an intact alternative complement pathway was required for our findings. The macrophages thus synthesize the active complement components of the alternative and terminal pathways in vitro.lld:pubmed
pubmed-article:3345254pubmed:languageenglld:pubmed
pubmed-article:3345254pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3345254pubmed:citationSubsetIMlld:pubmed
pubmed-article:3345254pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3345254pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3345254pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3345254pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3345254pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3345254pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3345254pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3345254pubmed:statusMEDLINElld:pubmed
pubmed-article:3345254pubmed:monthJanlld:pubmed
pubmed-article:3345254pubmed:issn0903-4641lld:pubmed
pubmed-article:3345254pubmed:authorpubmed-author:HetlandGGlld:pubmed
pubmed-article:3345254pubmed:authorpubmed-author:BungumLLlld:pubmed
pubmed-article:3345254pubmed:issnTypePrintlld:pubmed
pubmed-article:3345254pubmed:volume96lld:pubmed
pubmed-article:3345254pubmed:ownerNLMlld:pubmed
pubmed-article:3345254pubmed:authorsCompleteYlld:pubmed
pubmed-article:3345254pubmed:pagination89-92lld:pubmed
pubmed-article:3345254pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:meshHeadingpubmed-meshheading:3345254-...lld:pubmed
pubmed-article:3345254pubmed:year1988lld:pubmed
pubmed-article:3345254pubmed:articleTitleHuman peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report.lld:pubmed
pubmed-article:3345254pubmed:affiliationInstitute of Medical Biology, University of Tromsø, Norway.lld:pubmed
pubmed-article:3345254pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3345254pubmed:publicationTypeIn Vitrolld:pubmed